<b>Results:</b> Overall, the cumulative findings demonstrated that <i>CCND1</i> polymorphism (rs9344) was not significantly associated with cancer risk in all the genetic models studied (dominant model: GG vs GA+AA: OR (95%CI) = 0.81 (0.60-1.09), <i>P</i>=0.17; recessive model: GG+GA vs AA: OR (95%CI) = 1.23 (0.96-1.59), <i>P</i>=0.11; co-dominant model: <b>GG vs AA: OR (95%CI) = 1.35 (0.93-1.97), <i>P</i>=0.12;</b> co-dominant model: <b>(GG vs GA: OR (95%CI) = 1.16 (0.85-1.59), <i>P</i>=0.34</b>; allelic model: A vs G: OR (95%CI) = 1.20 (1.14-2.85), <i>P</i>=0.23; allelic model: G vs A: OR (95%CI) = 0.83 (0.62-1.12), <i>P</i>=0.23).
<b>Results:</b> Overall, the cumulative findings demonstrated that <i>CCND1</i> polymorphism (rs9344) was not significantly associated with cancer risk in all the genetic models studied (dominant model: GG vs GA+AA: OR (95%CI) = 0.81 (0.60-1.09), <i>P</i>=0.17; recessive model: GG+GA vs AA: OR (95%CI) = 1.23 (0.96-1.59), <i>P</i>=0.11; co-dominant model: <b>GG vs AA: OR (95%CI) = 1.35 (0.93-1.97), <i>P</i>=0.12;</b> co-dominant model: <b>(GG vs GA: OR (95%CI) = 1.16 (0.85-1.59), <i>P</i>=0.34</b>; allelic model: A vs G: OR (95%CI) = 1.20 (1.14-2.85), <i>P</i>=0.23; allelic model: G vs A: OR (95%CI) = 0.83 (0.62-1.12), <i>P</i>=0.23).
A significant association of CxCa with various polymorphisms was observed: rs1800797 in the IL-6 gene (odds ratio [OR] = 0.88, 95% confidence intervals [CI]: 0.79-0.99); rs1041981 in the LTA gene (OR = 0.87, 95% CI: 0.78-0.98), and rs9344 in the CCND1 gene (OR = 1.14, 95% CI: 1.02-1.27), for those individuals carrying the rare allele.
A significant association of CxCa with various polymorphisms was observed: rs1800797 in the IL-6 gene (odds ratio [OR] = 0.88, 95% confidence intervals [CI]: 0.79-0.99); rs1041981 in the LTA gene (OR = 0.87, 95% CI: 0.78-0.98), and rs9344 in the CCND1 gene (OR = 1.14, 95% CI: 1.02-1.27), for those individuals carrying the rare allele.
A significant association of CxCa with various polymorphisms was observed: rs1800797 in the IL-6 gene (odds ratio [OR] = 0.88, 95% confidence intervals [CI]: 0.79-0.99); rs1041981 in the LTA gene (OR = 0.87, 95% CI: 0.78-0.98), and rs9344 in the CCND1 gene (OR = 1.14, 95% CI: 1.02-1.27), for those individuals carrying the rare allele.
Additionally, a significant association with tumor grade was also observed for the rs603965 polymorphism in G versus A (allele comparison, p = 0.02, OR = 0.74, 95% CI 0.59-0.95, I<sup>2</sup> = 26%).
By grouping patients according to stage and radiation treatment, we compared SCCHN survival with regard to ERCC2 A35931C (Lys751Gln, rs13181) and CCND1 G870A (Pro241Pro, rs9344) genotypes.
For the rs603965 polymorphism of the CCND1 gene, we observed a protection effect for the colon cancer location under the dominant model (OR=0.49, P=0.0477).
For the rs603965 polymorphism of the CCND1 gene, we observed a protection effect for the colon cancer location under the dominant model (OR=0.49, P=0.0477).
Four single nucleotide polymorphisms (SNPs) in three genes were genotyped by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry [CCND1 Ex4-1G>A (rs9344), CDK7 Ex2-28C>T (rs2972388), ESR1 P325P Ex4-122G>C (rs1801132), and ESR1 T594T Ex8+229G>A (rs2228480)], and their associations with breast cancer risk were assessed.
Four single nucleotide polymorphisms (SNPs) in three genes were genotyped by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry [CCND1 Ex4-1G>A (rs9344), CDK7 Ex2-28C>T (rs2972388), ESR1 P325P Ex4-122G>C (rs1801132), and ESR1 T594T Ex8+229G>A (rs2228480)], and their associations with breast cancer risk were assessed.
However, in case of cervical cancer risk a non-significant association was reported under the recessive model (GG+GA vs AA: OR = 1.52, 95%CI = 0.60-3.90, <i>P</i>=0.38) with reference to <i>CCND1</i> polymorphism (rs9344).
However, in case of cervical cancer risk a non-significant association was reported under the recessive model (GG+GA vs AA: OR = 1.52, 95%CI = 0.60-3.90, <i>P</i>=0.38) with reference to <i>CCND1</i> polymorphism (rs9344).
However, in case of cervical cancer risk a non-significant association was reported under the recessive model (GG+GA vs AA: OR = 1.52, 95%CI = 0.60-3.90, <i>P</i>=0.38) with reference to <i>CCND1</i> polymorphism (rs9344).
In AL amyloidosis, rs9344 at the splice site of cyclin D1, promoting translocation (11;14), reached the highest significance, P=7.80 × 10<sup>-11</sup>; the SNP was only marginally significant in MM.